Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Isoliquiritigenin Induces Apoptosis via ROS-Mediated Inhibition of p38/mTOR/STAT3 Pathway in Human Melanoma Cells

  • Received : 2024.07.21
  • Accepted : 2024.10.08
  • Published : 2025.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Isoliquiritigenin (ISL), a phenolic compound derived from licorice, exhibits various biological activities, including anti-inflammatory, anti-viral, anti-tumor, and antioxidant effects. However, the molecular mechanisms underlying its anti-cancer effects are not well understood in SK-MEL-28 melanoma cells. Melanoma, a highly aggressive and treatment-resistant cancer, remains a significant health challenge. This study investigates the anti-cancer effects of ISL, focusing on identifying reactive oxygen species (ROS)-mediated apoptosis mechanisms on SK-MEL-28 melanoma cells. Our results show that ISL treatment induces apoptosis in SK-MEL-28 cells, as evidenced by the cleavage of caspase-9, -7, -3, and PARP. ISL increased Bax expression, decreased Bcl-2 expression, and promoted cytochrome C release into the cytosol. ISL also reduced the expression of cell cycle markers, including cyclin D1, D3, and survivin. Notably, ISL treatment markedly increased intracellular ROS levels and pretreatment with N-acetyl cysteine, a ROS scavenger, abrogated the ISL-induced inhibition of the p38/mTOR/STAT3 pathway and prevented apoptosis. Moreover, ISL significantly diminished the constitutive phosphorylation of mTOR and STAT3 in SK-MEL-28 cells by blocking the phosphorylation of p38 MAPK, an upstream kinase of mTOR. Pharmacological inhibition of mTOR attenuated the STAT3 signaling, indicating that mTOR acts as an upstream kinase of STAT3 in these cells. Collectively, these findings demonstrate that ISL inhibits SK-MEL-28 cell growth by downregulating cell survival proteins and inducing apoptosis through ROS generation.

Keywords

Acknowledgement

This research was funded by the Bisa Research Grant of Keimyung University in 2023 (Project No: 20230327).

References

  1. Basak, D., Arrighi, S., Darwiche, Y. and Deb, S. (2021) Comparison of anticancer drug toxicities: paradigm shift in adverse effect profile. Life (Basel) 12, 48. https://doi.org/10.3390/life12010048
  2. Bedard, K. and Krause, K. H. (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87, 245-313. https://doi.org/10.1152/physrev.00044.2005
  3. Bulavin, D. V. and Fornace, A. J., Jr. (2004) p38 MAP kinase's emerging role as a tumor suppressor. Adv. Cancer Res. 92, 95-118. https://doi.org/10.1016/S0065-230X(04)92005-2
  4. Chen, H. Y., Huang, T. C., Shieh, T. M., Wu, C. H., Lin, L. C. and Hsia, S. M. (2017) Isoliquiritigenin induces autophagy and inhibits ovarian cancer cell growth. Int. J. Mol. Sci. 18, 2025-2039. https://doi.org/10.3390/ijms18102025
  5. Choi, Y., Park, S., Lee, S., Shin, H. E., Kwon, S., Choi, J. K., Lee, M. H., Seo, S. Y. and Lee, Y. (2023) Cremastranone-derived homoisoflavanes suppress the growth of breast cancer cells via cell cycle arrest and caspase-independent cell death. Biomol. Ther. (Seoul) 31, 526-535. https://doi.org/10.4062/biomolther.2023.057
  6. Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P. and Prakash, O. (2019) Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front. Pharmacol. 10, 1614.
  7. Chun, K. S. and Joo, S. H. (2022) Modulation of reactive oxygen species to overcome 5-fluorouracil resistance. Biomol. Ther. (Seoul) 30, 479-489. https://doi.org/10.4062/biomolther.2022.017
  8. Conciatori, F., Ciuffreda, L., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F. and Milella, M. (2018) mTOR cross-talk in cancer and potential for combination therapy. Cancers 10, 23-52. https://doi.org/10.3390/cancers10010023
  9. Coulthard, L. R., White, D. E., Jones, D. L., McDermott, M. F. and Burchill, S. A. (2009) p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol. Med. 15, 369-379. https://doi.org/10.1016/j.molmed.2009.06.005
  10. Franklin, C., Livingstone, E., Roesch, A., Schilling, B. and Schadendorf, D. (2017) Immunotherapy in melanoma: recent advances and future directions. Eur. J. Surg. Oncol. 43, 604-611. https://doi.org/10.1016/j.ejso.2016.07.145
  11. Hernández, G., Lal, H., Fidalgo, M., Guerrero, A., Zalvide, J., Force, T. and Pombo, C. M. (2011) A novel cardioprotective p38-MAPK/mTOR pathway. Exp. Cell Res. 317, 2938-2949. https://doi.org/10.1016/j.yexcr.2011.09.011
  12. Hirchaud, F., Hermetet, F., Ablise, M., Fauconnet, S., Vuitton, D. A., Prétet, J. L. and Mougin, C. (2013) Isoliquiritigenin induces caspase-dependent apoptosis via downregulation of HPV16 E6 expression in cervical cancer Ca Ski cells. Planta Med. 79, 1628-1635. https://doi.org/10.1055/s-0033-1350956
  13. Hsu, Y. L., Kuo, P. L. and Lin, C. C. (2005) Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. Life Sci. 77, 279-292. https://doi.org/10.1016/j.lfs.2004.09.047
  14. Huynh, J., Chand, A., Gough, D. and Ernst, M. (2019) Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat. Rev. Cancer 19, 82-96. https://doi.org/10.1038/s41568-018-0090-8
  15. Hwang, S. Y., Wi, K., Yoon, G., Lee, C. J., Lee, S. I., Jung, J. G., Jeong, H. W., Kim, J. S., Choi, C. H., Na, C. S., Shim, J. H. and Lee, M. H. (2023) Licochalcone D inhibits skin epidermal cells transformation through the regulation of AKT signaling pathways. Biomol. Ther. (Seoul) 31, 682-691. https://doi.org/10.4062/biomolther.2023.162
  16. Jiang, H., Zuo, J., Li, B., Chen, R., Luo, K., Xiang, X., Lu, S., Huang, C., Liu, L., Tang, J. and Gao, F. (2023) Drug-induced oxidative stress in cancer treatments: angel or devil? Redox Biol. 63, 102754. https://doi.org/10.1016/j.redox.2023.102754
  17. Jung, J. I., Lim, S. S., Choi, H. J., Cho, H. J., Shin, H. K., Kim, E. J., Chung, W. Y., Park, K. K. and Park, J. H. (2006) Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J. Nutr. Biochem. 17, 689-696. https://doi.org/10.1016/j.jnutbio.2005.11.006
  18. Kim, D. H., Park, J. E., Chae, I. G., Park, G., Lee, S. and Chun, K. S. (2017) Isoliquiritigenin inhibits the proliferation of human renal carcinoma Caki cells through the ROS-mediated regulation of the Jak2/STAT3 pathway. Oncol. Rep. 38, 575-583. https://doi.org/10.3892/or.2017.5677
  19. Kim, N., Kwon, J., Shin, U. S. and Jung, J. (2023) Stimulatory anticancer effect of resveratrol mediated by G protein-coupled estrogen receptor in colorectal cancer. Biomol. Ther. (Seoul) 31, 655-660. https://doi.org/10.4062/biomolther.2023.072
  20. Lee, S. O., Joo, S. H., Kwak, A. W., Lee, M. H., Seo, J. H., Cho, S. S., Yoon, G., Chae, J. I. and Shim, J. H. (2021) Podophyllotoxin induces ROS-mediated apoptosis and cell cycle arrest in human colorectal cancer cells via p38 MAPK signaling. Biomol. Ther. (Seoul) 29, 658-666. https://doi.org/10.4062/biomolther.2021.143
  21. Li, M., Lu, G., Ma, X., Wang, R., Chen, X., Yu, Y. and Jiang, C. (2022) Anti-inflammation of isoliquiritigenin via the inhibition of NF-κB and MAPK in LPS-stimulated MAC-T cells. BMC Vet. Res. 18, 320.
  22. Li, Y., Zhao, H., Wang, Y., Zheng, H., Yu, W., Chai, H., Zhang, J., Falck, J. R., Guo, A. M., Yue, J., Peng, R. and Yang, J. (2013) Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of PI3K/Akt in human breast cancer. Toxicol. Appl. Pharmacol. 272, 37-48. https://doi.org/10.1016/j.taap.2013.05.031
  23. Liu, Y. X., Wang, J., Guo, J., Wu, J., Lieberman, H. B. and Yin, Y. (2008) DUSP1 is controlled by p53 during the cellular response to oxidative stress. Mol. Cancer Res. 6, 624-633. https://doi.org/10.1158/1541-7786.MCR-07-2019
  24. Luo, F., Tang, Y., Zheng, L., Yang, Y., Gao, H., Tian, S., Chen, H., Tang, C., Tang, S., Man, Q. and Wu, Y. (2023) Isoliquiritigenin inhibits the growth of colorectal cancer cells through the ESR2/PI3K/AKT signalling pathway. Pharmaceuticals (Basel) 17, 43. https://doi.org/10.3390/ph17010043
  25. Martínez-Limón, A., Joaquin, M., Caballero, M., Posas, F. and de Nadal, E. (2020) The p38 pathway: from biology to cancer therapy. Int. J. Mol. Sci. 21, 1913.
  26. Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J. and Siegel, R. L. (2022) Cancer treatment and survivorship statistics, 2022. CA Cancer J. Clin. 72, 409-436.
  27. Murugan, A. K. (2019) mTOR: role in cancer, metastasis and drug resistance. Semin. Cancer Biol. 59, 92-111. https://doi.org/10.1016/j.semcancer.2019.07.003
  28. Newsholme, P., Cruzat, V. F., Keane, K. N., Carlessi, R. and de Bittencourt, P. I., Jr. (2016) Molecular mechanisms of ROS production and oxidative stress in diabetes. Biochem. J. 473, 4527-4550. https://doi.org/10.1042/BCJ20160503C
  29. Obrador, E., Liu-Smith, F., Dellinger, R. W., Salvador, R., Meyskens, F. L. and Estrela, J. M. (2019) Oxidative stress and antioxidants in the pathophysiology of malignant melanoma. Biol. Chem. 400, 589-612. https://doi.org/10.1515/hsz-2018-0327
  30. Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D. and Garg, M. (2023) Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct. Target. Ther. 8, 375.
  31. Peng, F., Du, Q., Peng, C., Wang, N., Tang, H., Xie, X., Shen, J. and Chen, J. (2015) A review: the pharmacology of isoliquiritigenin. Phytother. Res. 29, 969-977. https://doi.org/10.1002/ptr.5348
  32. Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G. and Migliaccio, A. (2020) ROS in cancer therapy: the bright side of the moon. Exp. Mol. Med. 52, 192-203. https://doi.org/10.1038/s12276-020-0384-2
  33. Phan, T., Zhang, X. H., Rosen, S. and Melstrom, L. G. (2023) P38 kinase in gastrointestinal cancers. Cancer Gene Ther. 30, 1181-1189. https://doi.org/10.1038/s41417-023-00622-1
  34. Raut, P. K. and Park, P. H. (2020) Globular adiponectin antagonizes leptin-induced growth of cancer cells by modulating inflammasomes activation: critical role of HO-1 signaling. Biochem. Pharmacol. 180, 114186. https://doi.org/10.1016/j.bcp.2020.114186
  35. Redza-Dutordoir, M. and Averill-Bates, D. A. (2016) Activation of apoptosis signalling pathways by reactive oxygen species. Biochim. Biophys. Acta 1863, 2977-2992. https://doi.org/10.1016/j.bbamcr.2016.09.012
  36. Shakya, R., Byun, M. R., Joo, S. H., Chun, K. S. and Choi, J. S. (2023) Domperidone exerts antitumor activity in triple-negative breast cancer cells by modulating reactive oxygen species and JAK/STAT3 signaling. Biomol. Ther. (Seoul) 31, 692-699. https://doi.org/10.4062/biomolther.2023.173
  37. Siegel, R. L., Miller, K. D., Fuchs, H. E. and Jemal, A. (2022) Cancer statistics, 2022. CA Cancer J. Clin. 72, 7-33.
  38. Siegel, R. L., Miller, K. D., Wagle, N. S. and Jemal, A. (2023) Cancer statistics, 2023. CA Cancer J. Clin. 73, 17-48.
  39. Sim, S. J., Jang, J. H., Choi, J. S. and Chun, K. S. (2024) Domperidone, a dopamine receptor D2 antagonist, induces apoptosis by inhibiting the ERK/STAT3-mediated pathway in human colon cancer HCT116 cells. Biomol. Ther. (Seoul) 32, 568-576. https://doi.org/10.4062/biomolther.2024.048
  40. Son, Y., Cheong, Y. K., Kim, N. H., Chung, H. T., Kang, D. G. and Pae, H. O. (2011) Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways? J. Signal. Transduct. 2011, 792639. https://doi.org/10.1155/2011/792639
  41. Song, H. M., Park, G. H., Eo, H. J., Lee, J. W., Kim, M. K., Lee, J. R., Lee, M. H., Koo, J. S. and Jeong, J. B. (2015) Anti-proliferative effect of naringenin through p38-dependent downregulation of cyclin D1 in human colorectal cancer cells. Biomol. Ther. (Seoul) 23, 339-344. https://doi.org/10.4062/biomolther.2015.024
  42. Song, L., Luo, Y., Li, S., Hong, M., Wang, Q., Chi, X. and Yang, C. (2020) ISL induces apoptosis and autophagy in hepatocellular carcinoma via downregulation of PI3K/AKT/mTOR pathway in vivo and in vitro. Drug Des. Devel. Ther. 14, 4363-4376. https://doi.org/10.2147/DDDT.S270124
  43. Tang, L., Li, J., Fu, W., Wu, W. and Xu, J. (2019) Suppression of FADS1 induces ROS generation, cell cycle arrest, and apoptosis in melanocytes: implications for vitiligo. Aging (Albany N.Y.) 11, 11829-11843. https://doi.org/10.18632/aging.102452
  44. Tian, T., Sun, J., Wang, J., Liu, Y. and Liu, H. (2018) Isoliquiritigenin inhibits cell proliferation and migration through the PI3K/AKT signaling pathway in A549 lung cancer cells. Oncol. Lett. 16, 6133-6139.
  45. Villalpando-Rodriguez, G. E. and Gibson, S. B. (2021) Reactive oxygen species (ROS) regulates different types of cell death by acting as a rheostat. Oxid. Med. Cell. Longev. 2021, 9912436.
  46. Wang, T. T., Chen, Z. Z., Xie, P., Zhang, W. J., Du, M. Y., Liu, Y. T., Zhu, H. Y. and Guo, Y. S. (2019) Isoliquiritigenin suppresses the proliferation and induced apoptosis via miR-32/LATS2/Wnt in nasopharyngeal carcinoma. Eur. J. Pharmacol. 856, 172352.
  47. Wang, X. (2001) The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922-2933.
  48. Wang, Z. F., Liu, J., Yang, Y. A. and Zhu, H. L. (2020) A review: the anti-inflammatory, anticancer and antibacterial properties of four kinds of Licorice flavonoids isolated from Licorice. Curr. Med. Chem. 27, 1997-2011. https://doi.org/10.2174/0929867325666181001104550
  49. Wu, C. H., Chen, H. Y., Wang, C. W., Shieh, T. M., Huang, T. C., Lin, L. C., Wang, K. L. and Hsia, S. M. (2016) Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice. Oncotarget 7, 73432-73447. https://doi.org/10.18632/oncotarget.12369
  50. Xu, X., Zhi, T., Chao, H., Jiang, K., Liu, Y., Bao, Z., Fan, L., Wang, D., Li, Z., Liu, N. and Ji, J. (2018) ERK1/2/mTOR/Stat3 pathway-mediated autophagy alleviates traumatic brain injury-induced acute lung injury. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1663-1674. https://doi.org/10.1016/j.bbadis.2018.02.011
  51. Yang, H., Villani, R. M., Wang, H., Simpson, M. J., Roberts, M. S., Tang, M. and Liang, X. (2018) The role of cellular reactive oxygen species in cancer chemotherapy. J. Exp. Clin. Cancer Res. 37, 266. https://doi.org/10.1186/s13046-018-0909-x
  52. Ye, T., Zhu, S., Zhu, Y., Feng, Q., He, B., Xiong, Y., Zhao, L., Zhang, Y., Yu, L. and Yang, L. (2016) Cryptotanshinone induces melanoma cancer cells apoptosis via ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion. Biomed. Pharmacother. 82, 319-326. https://doi.org/10.1016/j.biopha.2016.05.015
  53. Yu, D., Liu, X., Zhang, G., Ming, Z. and Wang, T. (2018) Isoliquiritigenin inhibits cigarette smoke-induced COPD by attenuating inflammation and oxidative stress via the regulation of the Nrf2 and NF-kappaB signaling pathways. Front. Pharmacol. 9, 1001. https://doi.org/10.3389/fphar.2018.01001
  54. Yu, M., Pan, Q., Li, W., Du, T., Huang, F., Wu, H., He, Y., Wu, X. and Shi, H. (2023) Isoliquiritigenin inhibits gastric cancer growth through suppressing GLUT4 mediated glucose uptake and inducing PDHK1/PGC-1α mediated energy metabolic collapse. Phytomedicine 121, 155045. https://doi.org/10.1016/j.phymed.2023.155045
  55. Zhang, J., Wang, X., Vikash, V., Ye, Q., Wu, D., Liu, Y. and Dong, W. (2016) ROS and ROS-mediated cellular signaling. Oxid. Med. Cell. Longev. 2016, 4350965.
  56. Zhang, X., Yeung, E. D., Wang, J., Panzhinskiy, E. E., Tong, C., Li, W. and Li, J. (2010) Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells. Clin. Exp. Pharmacol. Physiol. 37, 841-847. https://doi.org/10.1111/j.1440-1681.2010.05395.x
  57. Zhang, Z., Chen, W. Q., Zhang, S. Q., Bai, J. X., Liu, B., Yung, K. K. and Ko, J. K. (2022) Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy. Phytomedicine 106, 154406. https://doi.org/10.1016/j.phymed.2022.154406
  58. Zhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J., Margolick, J. B., Liotta, L. A., Petricoin, E., 3rd and Zhang, Y. (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U. S. A. 104, 16158-16163. https://doi.org/10.1073/pnas.0702596104